Profile of glucose lowering drug use in outpatients with type 2 diabetes mellitus
BACKGROUND: The use of glucose lowering agents with favorable weight profile is a growing practice in Diabetology.
AIM: To characterize medication combinations in patients with type 2 Diabetes (T2D) and their effect on metabolic control.
MATERIAL AND METHODS: Review of medical records of 249 outpatients with T2D with a median age of 66 years, cared for at a medical network. Clinical characteristics, glycated hemoglobin (HbA1c), details of Diabetes treatment (types of drugs or insulin), renal function, lipids and B12 vitamin levels were registered.
RESULTS: The median disease duration was 16 years. The most recent HbA1c was 7.4%. No patient was using sulfonylureas, 45 were using Dipeptidyl peptidase 4 inhibitors, 113 were using Sodium-glucose Cotransporter-2 (SGLT2i) Inhibitors, 21 used Glucagon-like Peptide-1 Receptor Agonists (GLP1ra), 158 used basal insulin and 61 on basal plus bolus insulin. The use of SGLT2i or GLP1ra was associated with a metabolic control similar to those patients not using them, while patients on rapid insulin had a significantly worse metabolic control and a tendency to greater body mass index. The use of basal insulin and rapid insulin was significantly associated with more hypoglycemia events.
CONCLUSIONS: The use of SGLT2i and GLP1ra in patients with T2D is associated with better metabolic control than rapid insulin with less risk of hypoglycemia. The use of these therapies should be prioritized in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:150 |
|---|---|
| Enthalten in: |
Revista medica de Chile - 150(2022), 10 vom: 12. Okt., Seite 1334-1341 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Perfiles de hipoglicemiantes e insulinas en pacientes con diabetes mellitus tipo 2 y su efecto en control metabólico, hipoglicemia y otros efectos adversos |
|---|
| Beteiligte Personen: |
Grassi, Bruno A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug Combinations |
|---|
| Anmerkungen: |
Date Completed 21.11.2023 Date Revised 21.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4067/S0034-98872022001001334 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358594464 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358594464 | ||
| 003 | DE-627 | ||
| 005 | 20231226075100.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.4067/S0034-98872022001001334 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1195.xml |
| 035 | |a (DE-627)NLM358594464 | ||
| 035 | |a (NLM)37358092 | ||
| 035 | |a (PII)S0034-98872022001001334 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Grassi, Bruno A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Profile of glucose lowering drug use in outpatients with type 2 diabetes mellitus |
| 246 | 3 | 3 | |a Perfiles de hipoglicemiantes e insulinas en pacientes con diabetes mellitus tipo 2 y su efecto en control metabólico, hipoglicemia y otros efectos adversos |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.11.2023 | ||
| 500 | |a Date Revised 21.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The use of glucose lowering agents with favorable weight profile is a growing practice in Diabetology | ||
| 520 | |a AIM: To characterize medication combinations in patients with type 2 Diabetes (T2D) and their effect on metabolic control | ||
| 520 | |a MATERIAL AND METHODS: Review of medical records of 249 outpatients with T2D with a median age of 66 years, cared for at a medical network. Clinical characteristics, glycated hemoglobin (HbA1c), details of Diabetes treatment (types of drugs or insulin), renal function, lipids and B12 vitamin levels were registered | ||
| 520 | |a RESULTS: The median disease duration was 16 years. The most recent HbA1c was 7.4%. No patient was using sulfonylureas, 45 were using Dipeptidyl peptidase 4 inhibitors, 113 were using Sodium-glucose Cotransporter-2 (SGLT2i) Inhibitors, 21 used Glucagon-like Peptide-1 Receptor Agonists (GLP1ra), 158 used basal insulin and 61 on basal plus bolus insulin. The use of SGLT2i or GLP1ra was associated with a metabolic control similar to those patients not using them, while patients on rapid insulin had a significantly worse metabolic control and a tendency to greater body mass index. The use of basal insulin and rapid insulin was significantly associated with more hypoglycemia events | ||
| 520 | |a CONCLUSIONS: The use of SGLT2i and GLP1ra in patients with T2D is associated with better metabolic control than rapid insulin with less risk of hypoglycemia. The use of these therapies should be prioritized in the future | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Glycated Hemoglobin |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 700 | 1 | |a Hernández, Camila |e verfasserin |4 aut | |
| 700 | 1 | |a Boncompte, Mariana |e verfasserin |4 aut | |
| 700 | 1 | |a Henríquez, Camila |e verfasserin |4 aut | |
| 700 | 1 | |a L'huillier, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Miranda, Francisca |e verfasserin |4 aut | |
| 700 | 1 | |a Vrsalovic, Katica |e verfasserin |4 aut | |
| 700 | 1 | |a Rosales, Valentina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista medica de Chile |d 1945 |g 150(2022), 10 vom: 12. Okt., Seite 1334-1341 |w (DE-627)NLM00019624X |x 0717-6163 |7 nnns |
| 773 | 1 | 8 | |g volume:150 |g year:2022 |g number:10 |g day:12 |g month:10 |g pages:1334-1341 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4067/S0034-98872022001001334 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 150 |j 2022 |e 10 |b 12 |c 10 |h 1334-1341 | ||